CDMO Pfizer CentreOne opens new manufacturing facility in Japan
20 October 2017
Pfizer CentreOne, a global contract manufacturing organization embedded within Pfizer, announced that it is now offering services in Nagoya, Japan.
Advice for pharma in payer marketing? Ramp up digital, study finds
19 October 2017
It’s time for pharma to get digital in payer marketing. The most important audience in that field—the people making decisions about formulary placement—are digital-savvy researchers who prefer to find and receive information online, new research has found.
Joint projects may increase exports of medicines from Russia to Uzbekistan
18 October 2017
In 2018, the Russian pharmaceutical manufacturers intend to increase their exports to Uzbekistan up to more than $60 million. “According to our trade mission, the total volume of Uzbek imports of these products last year was $525 million, while the supplies from Russia amounted to about $50 million. Based on positive growth dynamics in this area over the recent years, Russian exports of medicinal products are projected to reach $56 million in 2017 and, in 2018, they will be worth more than $60 million,” said a source in the Russian trade mission.
Kaluga Pharmaceutical Cluster will become an entry point for German companies
18 October 2017
An agreement on cooperation between the Association of Kaluga Pharmaceutical Cluster and Steinbeis Global Institute Tübingen at the Steinbeis University Berlin was signed on October 16 by Irina Novikova, the Executive Director of the Association, and Prof. Dr. Bertram Lohmüller, Director of the Institute.
A big step forward in linking the genome to disease risk
18 October 2017
The human genome was first mapped about 15 years ago, but scientists have yet to gain a complete understanding of how genes maintain health—and how they govern the emergence of certain diseases. Now, a team of researchers led by Princeton University has taken a big step towards reaching that goal, publishing data related to 44 different human tissue types that they believe will help unlock the relationships between genetics and hard-to-treat diseases.
Syndax Announces $25 Million Registered Direct Offering of Common Stock
17 October 2017
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today announced that it has agreed to sell 2,021,018 shares of its common stock to Biotechnology Value Fund, L.P. and certain of its affiliates ("BVF") in a registered direct offering.
17 October 2017
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today announced that it has entered into an exclusive worldwide license agreement with Vitae Pharmaceuticals, Inc., a subsidiary of Allergan plc, for a portfolio of preclinical, orally-available small molecule inhibitors of the interaction of Menin with the Mixed Lineage Leukemia ("MLL") protein. These compounds have potential application in the treatment of a genetically-defined subset of acute leukemias with chromosomal rearrangements in the MLL gene ("MLL-r"). Syndax expects to initiate clinical studies in 2019.
A land plot was allocated for pharmaceutical complex construction near Moscow
17 October 2017
The Ministry of Property Relations of the Moscow Region supported the order “On Leasing Without a Tender a Land Plot Held in the State Unrestricted Ownership to Soyuzsnab-Zdorovye Limited Liability Company” issued by the Governor of the Moscow Region A.Yu. Vorobyov.
Russian government to simplify launch of new drugs
17 October 2017
The Russian government has prepared a bill simplifying the introduction of new drugs into the domestic pharmaceutical market, a spokesman of state press-service has said recently, reports The Pharma Letter’s local correspondent.
Russia viewed as one of the fastest growing pharma markets
16 October 2017
Russia’s pharmaceutical market is one of the fastest growing in the world and is expected to reach $36.61 billion by 2021, says a leading business information and analytics provider.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Putin has stated that Russia will support Africa in the struggle against epidemics
19 April 2024
The Russian government has expanded the list of vital and essential drugs
19 April 2024
Achieving FAIR bacterial identification
18 April 2024
Unique testing regimen could prevent nuclease contamination
18 April 2024